Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
In 1924 Ramon described the inactivation of diphtheria toxin by formaldehyde treatment. This method allowed the introduction of mass vaccination against diphtheria and tetanus and opened the way to the inactivation of viruses by chemical treatment. In this review we describe the use of genetic manipulations for the inactivation of pertussis toxin. The toxin inactivated by this new method is an antigen superior to those obtained by chemical treatment and has been used to develop a new vaccine against whooping cough.
Rappuoli
R
R
Sclavo Research Center, Siena, Italy.
Pizza
M
M
De Magistris
M T
MT
Podda
A
A
Bugnoli
M
M
Manetti
R
R
Nencioni
L
L
D000818:Animals; D001886:Bordetella pertussis; D006801:Humans; D051379:Mice; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D010566:Virulence Factors, Bordetella / Q000276:immunology* / Q000627:therapeutic use; D014917:Whooping Cough / Q000517:prevention & control
D010567:Pertussis Vaccine; D011994:Recombinant Proteins; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin